AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of “Hold” from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB – Get Rating) has earned an average recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $34.20.

Several analysts have recently commented on ANAB shares. JPMorgan Chase & Co. increased their target price on AnaptysBio from $24.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, November 18th. Guggenheim raised AnaptysBio from a “neutral” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Tuesday, November 1st. Wedbush upped their price target on AnaptysBio from $21.00 to $32.00 in a research note on Wednesday, November 9th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of AnaptysBio in a research note on Monday, September 19th. Finally, StockNews.com raised AnaptysBio from a “sell” rating to a “hold” rating in a research note on Friday.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $26.38 on Monday. The stock’s fifty day moving average is $28.10 and its 200-day moving average is $25.77. The stock has a market capitalization of $750.04 million, a PE ratio of -5.47 and a beta of -0.08. AnaptysBio has a 52 week low of $18.20 and a 52 week high of $34.33.

AnaptysBio (NASDAQ:ANAB – Get Rating) last announced its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.71). The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $17.36 million. AnaptysBio had a negative return on equity of 42.04% and a negative net margin of 3,003.32%. As a group, analysts forecast that AnaptysBio will post -4.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds have recently added to or reduced their stakes in ANAB. Quantbot Technologies LP acquired a new stake in shares of AnaptysBio during the second quarter worth about $34,000. US Bancorp DE raised its position in shares of AnaptysBio by 44.4% during the third quarter. US Bancorp DE now owns 1,538 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 473 shares during the period. Amalgamated Bank acquired a new stake in shares of AnaptysBio during the first quarter worth about $57,000. BNP Paribas Arbitrage SA raised its position in shares of AnaptysBio by 75.4% during the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 2,142 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of AnaptysBio during the third quarter worth about $211,000.

About AnaptysBio

(Get Rating)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.